Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Mutant isoforms of the KIT or PDGF receptors expressed by gastrointestinal stromal tumors (GISTs) are considered the therapeutic targets for STI571 (imatinib mesylate; Gleevec), a specific inhibitor of these tyrosine kinase receptors.Case reports of clinical efficacy of Gleevec in GISTs lacking the typical receptor mutations prompted a search for an alternate mode of action.Here we show that Gleevec can act on host DCs to promote NK cell activation.DC-mediated NK cell activation was triggered in vitro and in vivo by treatment of DCs with Gleevec as well as by a loss-of-function mutation of KIT.Therefore, tumors that are refractory to the antiproliferative effects of Gleevec in vitro responded to Gleevec in vivo in an NK cell-dependent manner.Longitudinal studies of Gleevec-treated GIST patients revealed a therapy-induced increase in IFN-γ production by NK cells, correlating with an enhanced antitumor response.These data point to a novel mode of antitumor action for Gleevec.Nonstandard abbreviations used: bi-injection daily (bid); bone marrow-derived DC (BM-DC); break point cluster region/Abelson leukemia virus (BCR/ABL); chronic myelogenous leukemia (CML); c-kit loss-of-function mutation (W/Wv); fms-like tyrosine 3 kinase ligand (FL); gastrointestinal stromal tumor (GIST); progression-free survival (PFS); stem cell factor (SCF); transporter associated with antigen processing (TAP).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Imatinib was arguably the first targeted anticancer agent to demonstrate immunostimulatory effects that are directly linked to NK-cell activation”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Borg et al., 2004
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389 · cited 1×
“Gleevec administration results in objective (partial or complete) response or stabilization in about 80% of GIST patients (6).”
BackgroundSelf-citationEffectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380 · cited 1×
“The renaissance of interest in NK cells in tumor immunosurveillance can be attributed to the discovery of stressinduced ligands for receptors that activate NK cells (23–25) and to the relevance of interactions between MHC class I molecules and killer inhibitory receptors in mismatched hematopoietic transplants, which…”
BackgroundActivation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C.-J., Joseph, N., Singer, S., Griffith, D. J., Haley, A., Town, A., et al. (2003) · Science · doi:10.1126/science.1079666 · Cited by 2,301 · cited 1×
“Somatic gain-of-function mutations of the c-kit protooncogene are found in 85% of GISTs (1), and recently, mutations of the PDGFRα chain were reported in 35% of the GISTs lacking the KIT mutations (2).”
BackgroundKinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., McGreevey, L. S., Chen, C.-J., Van den Abbeele, A. D., Druker, B. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.190 · Cited by 2,299 · cited 4×
“GISTs harboring an exon 11 mutation (76% of GISTs) exhibit the highest objective response rate and the longest time to progression (7).”
BackgroundTumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,592 · cited 1×
“Notably, in 50% of GIST-bearing patients, a fraction of circulating NK cells showed a downregulation of NKG2D expression at diagnosis (data not shown), which suggests that GISTs secrete soluble NKG2D ligands that might downregulate NKG2D expression on blood NK cells, similarly to the downregulation seen on T cells (30…”
BackgroundCosman, D., Müllberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. J. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,232
Maraskovsky, E., Brasel, K., Teepe, M., Roux, E. R., Lyman, S. D., Shortman, K., & McKenna, H. J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.5.1953 · Cited by 1,115 · cited 6×
“Since FL is known to amplify DCs, (14) and since mature DCs have the unique capacity to promote NK cell effector functions including IFN-γ secretion and antitumor effects in vivo (10, 15), we hypothesized that Gleevec could confer an NK cell stimulatory capacity to host DCs. Gleevec enhanced IFN-γ production by NK cel…”
BackgroundInfluentialRae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H. (2001) · Nature · doi:10.1038/35093109 · Cited by 1,083
Fernandez, N. C., Lozier, A., Flament, C., Ricciardi-Castagnoli, P., Bellet, D., Suter, M., Perricaudet, M., Tursz, T., Maraskovsky, E., & Zitvogel, L. (1999) · Nature Medicine · doi:10.1038/7403 · Cited by 1,060
Research works printed but not linked: 1
- Van Glabbeke, M.M., et al. 2003. Prognostic factors of toxicity and efficacy in patients with gastro-intes- tinal stromal tumors (GIST) treated with imatinib: A study of the EORTC-STBSG, ISG and AGITG [abstract]. Proc. Am. Soc. Clin. Oncol. 22:3286.
Cited by
Items 201–300 of 302
Nakano, A., Yoneyama, H., Ueha, S., Kitabatake, M., Ishikawa, S., Kawase, I., Sugiyama, H., & Matsushima, K. (2007) · International Immunopharmacology · doi:10.1016/j.intimp.2007.02.005 · Cited by 7
Chantharasamee, J., Adashek, J. J., Wong, K., Eckardt, M. A., Chmielowski, B., Dry, S., Eilber, F. C., & Singh, A. S. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00806-z · Cited by 9
Natural Killer Cells for Cancer Immunotherapy
Kosaka, Y., & Keating, A. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-980-2_4 · Cited by 6
“The tyrosine kinase inhibitor imatinib mesylate has also been found to act on DCs to activate NK cell-derived IFN-g production in patients with gastrointestinal stromal tumors [ 108 ].”
BackgroundUnravelling the complexity of cancer–immune system interplay
Fraser, C. K., Brown, M. P., Diener, K. R., & Hayball, J. D. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.66 · Cited by 8
Next questions for the medical treatment of gastrointestinal stromal tumor
Italiano, A. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000845 · Cited by 5
“For instance, imatinib favor antitumor immunity by several mechanisms including activation of cytotoxic T cells induction of Treg cells apoptosis through decreased tumor cells expression of the immunosuppressiveenzymeIDO[28] indirectactivationofnatural Killer (NK) cells and of IFN-g production through increasedKIT-inh…”
BackgroundLe futur des thérapeutiques ciblées en oncologie : trouver les cibles, traiter tôt et au long cours
Blay, J. (2007) · médecine/sciences · doi:10.1051/medsci/200723121073 · Cited by 5
“L’imatinib (Glivec®) (le prototype des molécules inhibant l’activité tyrosine kinase de BCR-ABL) exerce également des propriétés immuno-modulatrices, agissant sur l’interaction entre cellules dendritiques et lymphocytes natural killer (NK), ce qui contribue, au moins dans des modèles expérimentaux, à son activité anti…”
BackgroundImmunogenomic precision medicine: a personalized approach based on immunogenomic cancer evolution
Momoi, Y., Kumagai, S., & Nishikawa, H. (2025) · International Immunology · doi:10.1093/intimm/dxaf020 · Cited by 5
Effect of Chemotherapy on the Tumor Microenvironment and Anti-tumor Immunity
Meniawy, T. M., Nowak, A. K., & Lake, R. (2012) · Springer eBooks · doi:10.1007/978-94-007-4694-7_1 · Cited by 4
Némati, F., Mathiot, C., Grandjean, I., Lantz, O. J., Bordier, V., Dewulf, S., Ekue, R., Santo, J. P. D., Poupon, M., & Decaudin, D. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3281e444cb · Cited by 4
Bottino, C., Chiesa, M. D., Sorrentino, S., Morini, M., Vitale, C., Dondero, A., Tondo, A., Conte, M., Garaventa, A., & Castriconi, R. (2022) · Cancers · doi:10.3390/cancers14194548 · Cited by 4
Principles of NK Cell/DC Crosstalk: The Importance of Cell Dialogue for a Protective Immune Response
Lui, G., Carrega, P., & Ferlazzo, G. (2006) · Transfusion Medicine and Hemotherapy · doi:10.1159/000090197 · Cited by 4
Colorectal Mesenchymal Tumor: A Clinicopathologic Study of 25 Cases
Lee, C.-H., Jan, Y., Chen, J.-T., Ho, W. L., Wang, J. C. K., & Tseng, C. H. (2005) · Journal of the Chinese Medical Association · doi:10.1016/s1726-4901(09)70164-9 · Cited by 4
“Mutant isoforms of the KIT or PDGF receptors expressed by GISTs are considered the therapeutic targets for imatinib, which is a specific inhibitor of such tyrosine kinase receptors.(20) Phase I–III clinical trials demonstrated the efficacy of imatinib in the treatment of metastatic GISTs,(21) and it is possible that t…”
BackgroundZhang, L., Huang, J., Pi, Z., & Yu, M. (2015) · PubMed Central · Cited by 4
Gouw, L. G., Jones, K. B., Sharma, S., & Randall, R. L. (2011) · Cancers · doi:10.3390/cancers3044139 · Cited by 9
Yang, Y., Yu, M., Luo, L., Zhang, Z., Zeng, H., Chen, Y., Lin, Z., Chen, M., & Wang, W. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1405727 · Cited by 3
Nivolumab plus regorafenib in patients with small bowel adenocarcinoma: A case report
Zhang, G., Li, L., Dong, D., Qiu, H., Liu, T., Li, L., & Shen, G. (2021) · Medicine · doi:10.1097/md.0000000000024295 · Cited by 3
Une nouvelle cellule dendritique impliquée dans l’immunité anti-tumorale
Chaput, N., Taı̈eb, J., Ullrich, E., & Zitvogel, L. (2006) · médecine/sciences · doi:10.1051/medsci/20062267567 · Cited by 3
Brinch, C. M., Høgdall, E. V. S., Junker, N., Möeller, H., Sandfeld‐Paulsen, B., de Heer, P., Penninga, L., Rossen, P. B., Krarup‐Hansen, A., & Pedersen, N. A. (2022) · Cancers · doi:10.3390/cancers14235753 · Cited by 3
RETRACTED: The immunotherapy in gastrointestinal stromal tumors
Yu, G., Liu, R., Li, J., Zhao, G., & Wang, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33617 · Cited by 2
“…kinase KIT, Bauer et al. [20] reported that An individual with low KIT expression among GIST patients exhibited a positive response to imatinib treatment, while Borg et al. [21] noted that six patients lacking conventional imatinib target mutations also demonstrated sensitivity to imatinib therapy.”
BackgroundRetractedKim, S., Kim, H., Kim, E. J., Ryu, M., & Kang, Y. (2024) · BMC Cancer · doi:10.1186/s12885-024-13032-9 · Cited by 2
“Additionally, another study showed that imatinib induced the production of interferon gamma by natural killer cells, which correlated with its anti-tumor efficacy [14, 15].”
BackgroundVella, L. J., Andrews, M. C., Behren, A., Cebon, J. S., & Woods, K. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.929943 · Cited by 2
“Other proimmune effects of imatinib, including NK-cell activation [129], have been used to predict long-term survival in gastrointestinal stromal tumor-bearing patients [130].”
BackgroundSilencing c-Kit expression in human DCs suppresses Th2, Th17 response but enhances Th1 response.
Yang, B., Yang, Q., Huang, Q., Yan, H., Sun, T., & Tong, H. (2015) · PubMed · Cited by 2
Cancer is not just a disease of a tissue: It is a host disease
Apétoh, L., Ghiringhelli, F., Tesnière, A., Obéid, M., Mignot, G., Ullrich, E., Kroemer, G., & Zitvogel, L. (2008) · Annales d Endocrinologie · doi:10.1016/j.ando.2008.02.016 · Cited by 2
Pattar, V., Bagewadi, A., & Katti, V. (2016) · Cited by 2
Schultze, J. L. (2006) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-006-1091-z · Cited by 2
“Inzwischen ist aber klar, dass Imatinib gleichzeitig auch eine immunregulatorische Wirkung zugeschrieben werden kann [8].”
BackgroundCampbell, J. A. H., & Carayannopoulos, L. N. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.00604-7 · Cited by 2
Adams, S., Bhardwaj, N., & O’Neill, D. W. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6087-8_11 · Cited by 2
Kameda, H. (2009) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.32.77 · Cited by 2
The dialogue between natural killer cells and dendritic cells
Terme, M., Menard, C., Taı̈eb, J., Borg, C., Maruyama, K., Wakasugi, H., & Zitvogel, L. (2005) · International Congress Series · doi:10.1016/j.ics.2005.07.081 · Cited by 2
Dendritic Cells and Natural Killer Cells
Terme, M., & Zitvogel, L. (2006) · doi:10.1002/9783527619696.ch24 · Cited by 2
Combining Immunotherapies with Standard Therapies in the Treatment of Cancer
Pitt, J. M., Hannani, D., Vétizou, M., & Zitvogel, L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.17024-9 · Cited by 2
Precision Immunotherapy: Revolutionizing Cancer Treatment With Targeted Innovations
Ahn, M., Szabados, B. E., Ince, W., Kim, J., Ku, B. M., & Keenan, B. P. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-517508 · Cited by 1
Rössig, C. (2012) · OncoImmunology · doi:10.4161/onci.18401 · Cited by 3
Immunological evaluation for CML and its possibility for an immunotherapy
Fujii, S. (2009) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.32.231 · Cited by 1
In the Thick of the Fray: NK Cells in Inflamed Tissues
Marcenaro, E., Chiesa, M. D., Ferranti, B., & Moretta, A. (2007) · Springer eBooks · doi:10.1007/978-0-387-71767-8_2 · Cited by 1
Potential of imatinib mesylate as a novel treatment for pulmonary fibrosis
Chhina, M. K., Shlobin, O. A., Grant, G. M., & Nathan, S. D. (2008) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2.4.419 · Cited by 1
Radosavljevic, G. D., Jovanović, I., Martinova, K., Živić, D., Pejnovic, N. N., Arsenijević, N., & Lukić, M. L. (2012) · Serbian Journal of Experimental and Clinical Research · doi:10.5937/sjecr13-1726 · Cited by 1
TARGETING ONCOGENIC KINASE SIGNALING WITH SMALL MOLECULE KINASE INHIBITOR IMATINIB
Farooq, S., & Siddiqui, M. F. (2013) · Cited by 1
Immunopathology of Bone and Connective Tissue Cancers and Immunotherapy of Sarcomas
Narayanan, S., & Skitzki, J. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-57949-4_15 · Cited by 1
Cancer, Inflammasomes, and Adjuvanticity
Apétoh, L. (2011) · Springer eBooks · doi:10.1007/978-3-0348-0148-5_10 · Cited by 1
“Innate effectors such as gamma delta T-cells [12], natural killer cells (NK) [ 13 ], dendritic cells (DC) [14], and natural killer T-cells (NKT) [15], as well as membersofadaptiveimmuneresponses(B-andT-cells)haveindeedbeendescribed to restrain tumor progression [16].”
BackgroundCombination therapy for gastrointestinal stromal tumors: evidence from recent clinical trials
Ray-Coquard, I. L., Cassier, P. A., Labidi‐Galy, S. I., Heudel, P., Tassy, L., Chelghoum, M., Burghas, A., Méeus, P., & Blay, J. (2011) · Clinical Investigation · doi:10.4155/cli.11.59 · Cited by 2
Thérapies ciblées et immunomodulation dans les tumeurs solides
Fayette, J., & Blay, J. (2006) · Réanimation · doi:10.1016/j.reaurg.2006.06.013 · Cited by 1
Failure of immunological cells to eradicate tumor and cancer cells: an overview
Sharma, R. R., Talukdar, D., Malik, P., & Mukherjee, T. K. (2014) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-1404-117 · Cited by 2
“NK cells are the mainstay of immune systems participating in tumor-immune surveillance in various cancers (Borg et al., 2004; Castriconi et al., 2004; Waldhauer and Steinle, 2008).”
BackgroundEffects of Traditional Chinese Medicine on DCs Under Tumor Microenvironment
Zeng, Z., Xu, X., & Chen, D. (2015) · SpringerBriefs in biochemistry and molecular biology · doi:10.1007/978-94-017-7405-5_5 · Cited by 1
Growth Factor Signaling Pathways and Targeted Therapy
Swanson, K. D., Charest, A., Pollack, I. F., & Wong, E. T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812100-9.00021-8 · Cited by 1
Chelysheva, E., Gurianova, M. A., & Turkina, A. (2021) · Clinical oncohematology · doi:10.21320/2500-2139-2021-14-4-427-435 · Cited by 1
Olivares-Rivas, I., García‐Valverde, A., & Serrano, C. (2022) · Gastrointestinal Stromal Tumor · doi:10.21037/gist-21-11 · Cited by 1
Immunotherapy of gastrointestinal stromal tumors: current view and future directions
Boichuk, S., Abduraeva, S. A., & Kopnin, P. (2023) · Advances in molecular oncology · doi:10.17650/2313-805x-2023-10-2-17-29 · Cited by 1
Natural Killer Cells at the Tumors Microenvironment
Gazit, R., & Mandelboim, O. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6750-1_9 · Cited by 1
Interactions Between NK Cells and Regulatory T Cells
Terme, M., Chaput, N., & Zitvogel, L. (2009) · Springer eBooks · doi:10.1007/978-3-642-02309-5_18 · Cited by 2
Jajosky, A. N. (2014) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.5874 · Cited by 1
LaCasse, C. J. (2011) · UA Campus Repository (The University of Arizona)
Natural Killer Cells in the Treatment of Human Cancer
Malmberg, K., & Ljunggren, H. (2009) · Springer eBooks · doi:10.1007/978-3-642-02309-5_22
Anti-tumor and pro-tumor interactions of human NK cells in cancer
Wong, J. L. (2013) · D-Scholarship@Pitt (University of Pittsburgh)
Singh, N. K., Hodge, J. W., Madan, R. A., & Gulley, J. L. (2013) · Springer eBooks · doi:10.1007/978-94-007-6217-6_27
Novel Mechanisms In Dendritic Cells That Promote Th2 and Th17 But Not Th1 Responses In The Lung
Krishnamoorthy, N. (2008) · D-Scholarship@Pitt (University of Pittsburgh)
PET and PET/CT Imaging in Esophageal and Gastric Cancers
Dehdashti, F., & Siegel, B. A. (2006) · Springer eBooks · doi:10.1007/1-84628-187-3_11
“GISTs are generally characterized by a gain-offunction mutation of the Kit receptor and, occasionally, of the platelet-derived growth factor (PDGF) receptor a. Mutant isoforms of the Kit or PDGF receptors uniformly expressed by GIST are considered the therapeutic targets for imatinib mesylate (STI571, Gleevec), a spec…”
BackgroundVicente-Suarez, I., Villagra, A., & Sotomayor, E. M. (2007) · Springer eBooks · doi:10.1007/978-0-387-69118-3_9
“1+ cells (Borg et al. 2004).”
ResultActivation of Immune-Mediated Tumor Cell Death by Chemotherapy
McCoy, M. J., Nowak, A. K., & Lake, R. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5847-0_14
Autologous Natural Killer Cell/Natural Killer T Cell Immunotherapy of Malignant Diseases
Smith, A., Oertle, J. C., III, & Prato, D. (2014) · Open Journal of Medical Microbiology · doi:10.4236/ojmm.2014.43021
“Similarly, patients with gastrointestinal stromal tumors that received and responded to Gleevec, exhibited a significant increase in NK function compared to non-responding patients [90].”
ResultStrategies for immune intervention
Schaft, N., & Dörrie, J. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0113-7
Chronic myeloid leukemia and allogeneic natural killer cells: a surprising dialogue
Wittnebel, S., Bourhis, J.-H., & Caignard, A. (2006) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2.4.627
Immunological implications of the use of tyrosine kinase inhibitors in chronic myeloid leukemia
Rodrigues, C. D. S., Mendonça, L. M., de Oliveira, J. R., Napimoga, M. H., & Abreu, M. T. C. L. (2012) · Journal of Hematological Malignancies · doi:10.5430/jhm.v2n3p45
Radosavljevic, G. D., Jovanović, I., Martinova, K., Živić, D., Pejnovic, N. N., Arsenijević, N., Lukić, M. L., & Lukić, M. L. (2012)
(protein kinase / protein kinase inhibitor / cancer therapy)
Shchemelinin, I. (2006)
Critical appraisal of the current status of dendritic cell based therapy
Tirapu, I., Huarte, E., Alfaro, C., Arina, A., Murillo, O., Inogés, S., Bendandi, M., Mazzolini, G. D., & Melero, I. (2005)
Chaput, N., Taı̈eb, J., Ullrich, E., & Zitvogel, L. (2015)
Immunstimulatorische RNA-Oligonukleotide aktivieren T- und NK-Zellen über Toll-like-Rezeptor 7
München, L.-M.-U. (2010)
Kokura, S. (2016) · Springer eBooks · doi:10.1007/978-4-431-55031-0_7 · Cited by 1
Interferon-producing killer dendritic cells (IKDC)
Housseau, F. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-370454-2.00003-x
Mignot, G. (2009) · OpenGrey (Institut de l'Information Scientifique et Technique)
The Role of Innate Immunity in the Pathogenesis and Treatment of Experimental Pulmonary Hypertension
Ormiston, M. L. (2006) · TSpace (University of Toronto)
The Secrets of T Cell Polarization
Vargas, T. R., & Apétoh, L. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_5 · Cited by 1
Blay, J. (2015) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)31004-0
“Imatinib, en bloquant notamment des voies de signalisation inhibant leur fonction, réactive les cellules dendritique in vitre, in vivo dans les modèles précliniques, et in vivo chez les patients, ce phénomène constituant un marqueur pharmacodynamique prédictif de la réponse dans ce travail [40, 41].”
BackgroundRe, G. L., Conte, A. D., Re, F. L., Doretto, P., Ubiali, P., Brosolo, P., Sulfaro, S., & Marus, W. (2019) · Surgical Case Reports · doi:10.31487/j.scr.2019.03.03
How does autophagy affect tumor-infiltrating immune cells?
Jacquin, É., Garcia, A. B., & Apétoh, L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819609-0.00005-5
Role of IL-17 and IL-17 Family Cytokines on Tumor Development
Végran, F., Berger, H., & Apétoh, L. (2012) · Springer eBooks · doi:10.1007/978-3-0348-0522-3_16 · Cited by 1
(2004) · Nature reviews. Cancer · doi:10.1038/nrc1443
STAT Transcription Factors: Controlling All Aspects of NK Cell Biology
Putz, E. M., Zebedin, E., & Sexl, V. (2012) · Springer eBooks · doi:10.1007/978-3-7091-0891-8_12
Growth factor signaling pathways and targeted therapy
Aulakh, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27356-8.00061-9
Aspects fonctionnels et pronostiques des cellules myéloïdes suppressives et de Foxp3 dans le cancer
Ladoire, S. (2011) · theses.fr (ABES) · doi:10.70675/f95be627zd09cz4fd2za49fz6b11ffb7363d
The role of human Natural Killer cells (NK) in anti-tumour immune responses
Fregni, G. (2011) · theses.fr (ABES) · doi:10.70675/ec12d6aaz92d6z4c3az8410zc0c6807a0e9b
Semeraro, M. (2013) · theses.fr (ABES) · doi:10.70675/215d1a18z5598z4bc3zbc57z9fb4e3ac997c · Cited by 1
Celis‐Gutierrez, J. (2014) · theses.fr (ABES) · doi:10.70675/9a0f10e8zdf71z4feaz991cz3baf64da5229
Elaboration de nouvelles stratégies d'immunothérapie dans les leucémies aigües
Roy, A. L. (2015) · theses.fr (ABES) · doi:10.70675/fda42f6dz8d29z4ca9za484zccec301cfb1d
Crizotinib-Induced Immunogenic Cell Death in Non-Small Cell Lung Cancer
Liu, P. (2018) · theses.fr (ABES) · doi:10.70675/ed550df1z9febz41d6z9846z294a6695b865
Shekarian, T. (2017) · theses.fr (ABES) · doi:10.70675/31550ddbz6cf7z4e25za126z01b3fb8737f1
Etude phénotypique et fonctionnelle des cellules NK dans un contexte de cancer et d'inflammation
Picard, É. (2017) · theses.fr (ABES) · doi:10.70675/43ce92f0z4ba9z4d80zbf69z0d61fe38a8c1
Cayssials, É. (2020) · theses.fr (ABES) · doi:10.70675/6c8b6f93zb528z4772zbc3fza6d80ab163c0 · Cited by 1
Chen, Z., Zhou, F., Tian, J., Lv, Q., Wang, D., & Fan, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1692792
Natural Killer Cells in the Skin and Lymphoid Tissues
Johnson, K. M., & Lee, D. A. (2026) · Springer eBooks · doi:10.1007/978-3-662-68816-8_72-1
Metadata
- Authors
- Borg, C., Terme, M., Taïeb, J., Ménard, C., Flament, C., Robert, C., Maruyama, K., Wakasugi, H., Angevin, E., Thielemans, K., Cesne, A. L., Chung-Scott, V., Lazar, V., Tchou, I., Crépineau, F., Lemoine, F., Bernard, J., Fletcher, J. A., Turhan, A., Blay, J.-Y., Spatz, A., Emile, J.-F., Heinrich, M. C., Mécheri, S., Tursz, T., & Zitvogel, L.
- Affiliations
- Inserm (FR)
- National Cancer Centre Japan (JP)
- Vrije Universiteit Brussel (BE)
- Institut Gustave Roussy (FR)
- Institut Jean Godinot (FR)
- Harvard University (US)
- Hospices Civils de Lyon (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Oregon Health & Science University (US)
- Corresponding author
- Zitvogel, Laurence
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2004-08-01
- Volume
- 114
- Issue
- 3
- Pages
- 379-388
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC489961
- OpenAlex
- W2161785083
- Cited by
- 302
- References
- 35
- Citations by year
- 2026: 5 · 2025: 1 · 2024: 4 · 2023: 3 · 2022: 11 · 2021: 8 · 2020: 13 · 2019: 9 · 2018: 4 · 2017: 11 · 2016: 14 · 2015: 19 · 2014: 16 · 2013: 24 · 2012: 19
- FWCI
- 16.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Institut National de la Santé et de la Recherche Médicale
- Hospices Civils de Lyon
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Keywords
- imatinib mesylate, gastrointestinal stromal tumor, NK cell activation, dendritic cells, interferon-gamma, antitumor immunity, PDGF receptor, stem cell factor
- MeSH terms
- Imatinib Mesylate, Animals, Antineoplastic Agents, Benzamides, Dendritic Cells, Enzyme Inhibitors, Female, Gastrointestinal Neoplasms, Humans, Interferon-gamma, Killer Cells, Natural, Leukocytes, Mononuclear, Longitudinal Studies, Mice, Inbred C57BL, Mutation, Piperazines, Protein-Tyrosine Kinases, Pyrimidines, Gene Expression Regulation, Neoplastic, Case-Control Studies, Mice, SCID, Stromal Cells, Receptors, Platelet-Derived Growth Factor, Mice, Knockout, Neutrophil Activation, Coculture Techniques, Proto-Oncogene Proteins c-kit, Receptor Protein-Tyrosine Kinases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.